Clinical trials: Obesity (BMI>30), open to volunteers
Type 2 Diabetes Mellitus (T2D), Obesity (BMI>30)
Impact of Endoscopic Sleeve Gastroplasty (ESG) in Obese Adults With Type 2 Diabetes (T2D)
The goal of this clinical trial is to determine whether Endoscopic Sleeve Gastroplasty (ESG)-induced weight loss can improve glycemic outcomes and alter the trajectory toward insulin dependence in adults with obesity and…
- Trial name
- MEASURE (NCT07639684)
- Testing
- ESG with OverStitch
- Volunteers
- 50 people
- Sponsor
- Boston Scientific Corporation
Obesity / Overweight, Obesity (BMI Equal to or >30)
A PHASE 2A, EXPLORATORY, RANDOMIZED, SINGLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY OF WEIGHT LOSS INDUCED BY NKS-3 IN OBESE ADULTS.
This study is designed as a single-blind, placebo-controlled, randomized, parallel-group trial. Subjects will be randomized in a 2:1 ratio to receive either NKS-3 or matching placebo, with a total planned enrollment of 31…
- Trial name
- SERENITY-1 (NCT07882654)
- Testing
- Investigational product is a modified linoleic acid, named NKS-3. This non-caloric agent, synthetized from linoleic acid, is a fat taste receptors agonist, targeting CD36 with also an impact on GPR120
- Where
- Tunisia
- Volunteers
- 31 people
- Sponsor
- EktaH
Obese With Comorbidities, Obese Patients (BMI ≥ 30 kg/m²)
A Study to Investigate the Efficacy and Safety of Two Different Doses of Twice Daily Distal Jejunal-release Dextrose Beads Formulations Combined With a Gel Composition Compared to Placebos in Obese Subjects With Weight Related Comorbidities
The goal of this randomized, double-blind, placebo-controlled, phase IIa study is to demonstrate superiority on body weight reduction of two different doses of twice daily distal jejunal-release dextrose beads formulations (APHD…
- Trial name
- NCT07008456
- Testing
- APHD-012, APHD-002, APHP-012
- Where
- 6 sites in Georgia
- Volunteers
- 102 people
- Sponsor
- Aphaia Pharma US LLC
Obese Adults
A Phase 1 Study of VK2735 in Obese Adults Without Comorbidities
The goal of this Phase 1, randomized, double-blind, placebo-controlled study is to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of VK2735 in adults who are obese (BMI ≥ 30 kg/m2) without comorbidities.
- Trial name
- NCT07838740
- Testing
- VK2735 Drug
- Where
- 2 sites in United States
- Volunteers
- 270 people
- Sponsor
- Viking Therapeutics, Inc.
Obesity (BMI>30), Obesity & Overweight
Allurion Gastric Balloon PAS
The primary purpose of this study is to confirm the safety profile results for the Allurion Gastric Balloon System (AGBS).
- Trial name
- NCT07684664
- Testing
- Active Elipse Device
- Volunteers
- 250 people
- Sponsor
- Allurion Technologies
Overweight and Obese Adults, Obese Patients (BMI ≥ 30 kg/m²)
Eatit's Obesity Intervention: Effects on Weight, Eating Habits and Health
Obesity is a growing public health problem in Sweden, but access to care varies depending on geographical location. Eatit´s multimodal digitally dietitian-supported lifestyle intervention offers an accessible treatment…
- Trial name
- NCT07183228
- Testing
- Lifestyle Intervention for Obesity
- Where
- Sweden
- Volunteers
- 93 people
- Sponsor
- Eatit AB